Volume | 69,800 |
|
|||||
News | - | ||||||
Day High | 0.10 | Low High |
|||||
Day Low | 0.0311 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Canaquest Medical Corporation (PK) | CANQF | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.0403 | 0.0311 | 0.10 | 0.10 | 0.11 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
12 | 69,800 | US$ 0.037466 | US$ 2,615 | - | 0.03 - 0.4399 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
14:52:12 | 100 | US$ 0.10 | USD |
Canaquest Medical Corporation (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 2.07M | 20.66M | 4.35M | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Canaquest Medical (PK) News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CANQF Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.07 | 0.1199 | 0.0311 | 0.109934 | 14,722 | 0.03 | 42.86% |
1 Month | 0.1499 | 0.1499 | 0.0311 | 0.1157359 | 11,974 | -0.0499 | -33.29% |
3 Months | 0.1796 | 0.1799 | 0.03 | 0.1165202 | 11,479 | -0.0796 | -44.32% |
6 Months | 0.27 | 0.37 | 0.03 | 0.1776611 | 9,030 | -0.17 | -62.96% |
1 Year | 0.20 | 0.4399 | 0.03 | 0.1770452 | 6,670 | -0.10 | -50.00% |
3 Years | 0.24 | 0.4399 | 0.03 | 0.1975153 | 3,672 | -0.14 | -58.33% |
5 Years | 0.12 | 0.44 | 0.0201 | 0.1865655 | 4,327 | -0.02 | -16.67% |
Canaquest Medical (PK) Description
CanaQuest Medical, an award-winning, Clinical Stage/Life-Sciences Company, is focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system utilizing specific brain receptors. The drug candidate targeted for human trials is the result of R&D for cannabidiol formulations plus a drug delivery system maximizing bioavailability. The Company is working with consultants and has mapped out the regulatory pathway for a Drug Identification Number (DIN) for epilepsy, including initiating human trials, with the US - FDA and Health Canada. CanaQuest is the industry partner for research and product development with Dr. Steven Laviolette, a professor, and neuroscientist, at Western University. |